Evidence map›Paper›PMID 29366838›Full record

ArticleBone2019

Development of a 3D bone marrow adipose tissue model.

Heather Fairfield, Carolyne Falank, Mariah Farrell, Calvin Vary, Joshua M Boucher, Heather Driscoll, Lucy Liaw, Clifford J Rosen, Michaela R Reagan

Abstract read
In one paragraph

Article in Bone, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 69 citations in OpenAlex.

  1. Trial
  2. Article
  3. Nerve tissue model on a micropatterned surface: Axon guidance and neural regeneration.Journal of materials science. Materials in medicine · 2025
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Microfabricated Organ-Specific Models of Tumor Microenvironments.Annual review of biomedical engineering · 2025
    Review
  10. Article
  11. Organoids technology in cancer research: from basic applications to advancedFrontiers in cell and developmental biology · 2025
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Heather FairfieldMaine Medical Center Research Institute, Scarborough, ME 04074, USA; University of Maine Graduate School of Biomedical Science and Engineering, Orono, ME 04469, USA; Tufts University School of Medicine, Boston, MA 02111, USA.
Carolyne FalankMaine Medical Center Research Institute, Scarborough, ME 04074, USA; University of Maine Graduate School of Biomedical Science and Engineering, Orono, ME 04469, USA; Tufts University School of Medicine, Boston, MA 02111, USA.
Mariah FarrellMaine Medical Center Research Institute, Scarborough, ME 04074, USA; University of Maine Graduate School of Biomedical Science and Engineering, Orono, ME 04469, USA; Tufts University School of Medicine, Boston, MA 02111, USA.
Calvin VaryMaine Medical Center Research Institute, Scarborough, ME 04074, USA; University of Maine Graduate School of Biomedical Science and Engineering, Orono, ME 04469, USA; Tufts University School of Medicine, Boston, MA 02111, USA.
Joshua M BoucherMaine Medical Center Research Institute, Scarborough, ME 04074, USA; University of Maine Graduate School of Biomedical Science and Engineering, Orono, ME 04469, USA; Tufts University School of Medicine, Boston, MA 02111, USA.
Heather DriscollVermont Genetics Network, Department of Biology, Norwich University, 158 Harmon Drive, Northfield, VT 05663, USA.
Lucy LiawMaine Medical Center Research Institute, Scarborough, ME 04074, USA; University of Maine Graduate School of Biomedical Science and Engineering, Orono, ME 04469, USA; Tufts University School of Medicine, Boston, MA 02111, USA.
Clifford J RosenMaine Medical Center Research Institute, Scarborough, ME 04074, USA; University of Maine Graduate School of Biomedical Science and Engineering, Orono, ME 04469, USA; Tufts University School of Medicine, Boston, MA 02111, USA.
Michaela R ReaganMaine Medical Center Research Institute, Scarborough, ME 04074, USA; University of Maine Graduate School of Biomedical Science and Engineering, Orono, ME 04469, USA; Tufts University School of Medicine, Boston, MA 02111, USA. Electronic address: Mreagan@mmc.org.
Maine Medical Center · USMaine Medical Center Research Institute · USTufts University · USUniversity of Maine · USNorwich University Applied Research Institute · US

Funding

Vermont INBRE Administrative Supplement 2024 AWD 118P20GM103449 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI CHRISTOPHER S FRANCKLYN · 2012 to 2026
$58.4M
Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted InterventionsU54GM115516 · NIGMS · MAINEHEALTH · PI Frances E. Carr · 2017 to 2026
$51.6M
The role of night shift work in metabolic disorders during and after pregnancyP20GM121301 · NIGMS · MAINEHEALTH · PI CLIFFORD JAMES ROSEN · 2017 to 2026
$25.1M
Translational Bioreactors - Engineering Complex TissuesP41EB002520 · NIBIB · TUFTS UNIVERSITY MEDFORD · PI KAPLAN, DAVID L. · 2004 to 2018
$16.7M
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism & Energy BalanceR24DK092759 · NIDDK · MAINEHEALTH · PI HOROWITZ, MARK C, MACDOUGALD, ORMOND A · 2011 to 2019
$13.0M
Progenitor Cell Analysis CoreP30GM106391 · NIGMS · MAINEHEALTH · PI WOJCHOWSKI, DON MICHAEL · 2013 to 2017
$5.7M
Phase III COBRE in Vascular BiologyP30GM103392 · NIGMS · MAINEHEALTH · PI ST. GERMAIN, DONALD L. · 2012 to 2016
$4.7M
Skeletal Phenotyping CoreP30AR066261 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI KRONENBERG, HENRY M. · 2014 to 2018
$3.5M
Interdisciplinary study of marrow adiposity, mineral metabolism,and energy balancR24DK084970 · NIDDK · MAINEHEALTH · PI HOROWITZ, MARK C, KLIBANSKI, ANNE · 2010 to 2010
$501k
NIAMS NIH HHS P30 AR066261NIDDK NIH HHS R24 DK084970NIDDK NIH HHS R24 DK092759NIGMS NIH HHS P20 GM103449NIGMS NIH HHS P20 GM121301NIGMS NIH HHS P30 GM103392NIGMS NIH HHS P30 GM106391NIGMS NIH HHS U54 GM115516
6 · The paper itself

Abstract

Over the past twenty years, evidence has accumulated that biochemically and spatially defined networks of extracellular matrix, cellular components, and interactions dictate cellular differentiation, proliferation, and function in a variety of tissue and diseases. Modeling in vivo systems in vitro has been undeniably necessary, but when simplified 2D conditions rather than 3D in vitro models are used, the reliability and usefulness of the data derived from these models decreases. Thus, there is a pressing need to develop and validate reliable in vitro models to reproduce specific tissue-like structures and mimic functions and responses of cells in a more realistic manner for both drug screening/disease modeling and tissue regeneration applications. In adipose biology and cancer research, these models serve as physiologically relevant 3D platforms to bridge the divide between 2D cultures and in vivo models, bringing about more reliable and translationally useful data to accelerate benchtop to bedside research. Currently, no model has been developed for bone marrow adipose tissue (BMAT), a novel adipose depot that has previously been overlooked as "filler tissue" but has more recently been recognized as endocrine-signaling and systemically relevant. Herein we describe the development of the first 3D, BMAT model derived from either human or mouse bone marrow (BM) mesenchymal stromal cells (MSCs). We found that BMAT models can be stably cultured for at least 3 months in vitro, and that myeloma cells (5TGM1, OPM2 and MM1S cells) can be cultured on these for at least 2 weeks. Upon tumor cell co-culture, delipidation occurred in BMAT adipocytes, suggesting a bidirectional relationship between these two important cell types in the malignant BM niche. Overall, our studies suggest that 3D BMAT represents a "healthier," more realistic tissue model that may be useful for elucidating the effects of MAT on tumor cells, and tumor cells on MAT, to identify novel therapeutic targets. In addition, proteomic characterization as well as microarray data (expression of >22,000 genes) coupled with KEGG pathway analysis and gene set expression analysis (GSEA) supported our development of less-inflammatory 3D BMAT compared to 2D culture. In sum, we developed the first 3D, tissue-engineered bone marrow adipose tissue model, which is a versatile, novel model that can be used to study numerous diseases and biological processes involved with the bone marrow.

Indexed as

Models, BiologicalAdipose TissueAnimalsBone MarrowCell Line, TumorFemaleGene Expression RegulationHumansLipidsMaleMesenchymal Stem CellsMice, Inbred C57BLMultiple MyelomaProteomicsSilkTissue EngineeringLipidsSilk3DBone marrow adiposeMultiple myelomaSilk scaffoldsTissue engineering

Identifiers

PMID29366838
PMCPMC6062483
OpenAlexW2793739876

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.